Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered Microbial Medicines (GEMMs).
Location: United States, California, South San Francisco
Employees: 11-50
Total raised: $76.5M
Founded date: 2016
Investors 4
| Date | Name | Website |
| - | Alta Partn... | altapartne... |
| - | Touchdown ... | touchdownv... |
| - | 5AM Ventur... | 5amventure... |
| - | DCVC | dcvc.com/ |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 13.09.2022 | Series B | $43.5M | - |
| 07.01.2020 | Series A | $33M | - |
Mentions in press and media 9
| Date | Title | Description |
| 14.09.2022 | Genentech-partnered Novome lands $43.5M to push gastrointestinal drug through mid-stage study | A biotech with connections to Roche’s Genentech has now landed its newest cash infusion. Microbiome outfit Novome Biotechnologies said Tuesday that it has now secured $43.5 million in new financing via a Series B round. Th... |
| 13.09.2022 | Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes | /EIN News/ -- - Funding supports ongoing Phase 2a clinical trial in patients with enteric hyperoxaluria, and pipeline of GEMMs candidates for inflammatory bowel disease - - Financing includes new investors led by Tencent, with participation... |
| 13.09.2022 | Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes | - |
| 13.09.2022 | Novome gets $43.5M boost for its engineered microbiome therapies | Novome Biotechnologies — a South San Francisco-based biotech focused on genetically engineered microbial medicines (GEMMs) — raised $43.5 million in Series B funds on Tuesday. The funding round was led by Tencent. Other investors — Universi... |
| 13.09.2022 | Novome Biotechnologies Raises $43.5 Million Series B Financing to Advance its Pipeline of Therapeutically Engineered Microbes | - Funding supports ongoing Phase 2a clinical trial in patients with enteric hyperoxaluria, and pipeline of GEMMs candidates for inflammatory bowel disease - - Financing includes new investors led by Tencent, with participation from existing... |
| 09.01.2020 | Novome Biotechnologies Secures $33M in Series A Financing | Novome Biotechnologies, Inc., a South San Francisco, Calif.-based biotechnology company engineering living medicines for chronic diseases, secured $33m in Series A financing. The round was led by DCVC Bio with participation from seed invest... |
| 08.01.2020 | Daily funding roundup - January 8th, 2020 | Midnite raised $2.5M; Fishbowl landed $5.3M; Legalpad has secured $10M; Deep Genomics closed $30M Midnite: Midnite is an e-sports betting startup. Midnite has raised $2.5 million led by Makers Fund. Read more Fishbowl: Fishbowl is a social ... |
| 07.01.2020 | Novome Biotechnologies Raises $33 Million Series A Financing and Appoints Blake Wise as Chief Executive Officer | - |
| - | Novome Biotechnologies | “Novome Biotechnologies - Engineering Living Medicines” |